Abstract
A 43-year-old patient developed factor V inhibitor 6 months after liver transplantation for primary biliary cirrhosis in association with Sjögren's syndrome/systemic lupus erythematosus. She suffered from ecchymoses in the lower extremities. The factor V inhibitor was eradicated after 10 weekly doses of 375-500 mg/m2 rituximab.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 363-365 |
| Number of pages | 3 |
| Journal | American Journal of Hematology |
| Volume | 77 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 2004 |
Keywords
- Factor V inhibitor
- Primary biliary cirrhosis
- Rituximab
- Sjögren's syndrome
- Systemic lupus erythematosus
ASJC Scopus subject areas
- Hematology
Fingerprint Dive into the research topics of 'Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis'. Together they form a unique fingerprint.
Cite this
Lian, E. C. Y., Tzakis, A. G., & Andrews, D. (2004). Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis. American Journal of Hematology, 77(4), 363-365. https://doi.org/10.1002/ajh.20181